LLY · 10-Q · 2026Q2 · Full report
Product / Drug Pipeline Progress
ELI LILLY & Co · 2026-08-05 · Importance 31 · Surprise 42 · In source text
Lilly reported positive Phase 3 primary-endpoint results for retatrutide in obesity and for type 2 diabetes. It initiated Phase 3 trials for eloralintide as an incretin add-on for obesity and for obstructive sleep apnea and osteoarthritis pain. The company also advanced insulin efsitora alfa, baricitinib, brenipatide, and sofetabart mipitecan, including a positive EU CHMP opinion for efsitora and FDA Breakthrough Therapy designation for sofetabart in certain platinum-resistant ovarian cancer patients.
Key facts
- The company submitted orforglipron for type 2 diabetes in the U.S., the EU, and Japan. source
- The CHMP issued a positive opinion recommending insulin efsitora alfa for the treatment of type 2 diabetes in the EU. source
- Phase 3 trials for retatrutide for obesity met their primary endpoints; a Phase 3 trial for retatrutide for type 2 diabetes met the primary endpoint. source
- A Phase 3 trial was initiated for baricitinib for type 1 diabetes. source
- Phase 3 trials were initiated for eloralintide as incretin add-on for obesity, for obstructive sleep apnea (OSA), and for osteoarthritis (OA) pain. source
- A Phase 3 trial was initiated for brenipatide for major depressive disorder. source
- A Phase 3 trial was initiated for sofetabart mipitecan for platinum-sensitive ovarian cancer, and the FDA granted Breakthrough Therapy designation for sofetabart mipitecan for certain patients with platinum-resistant ovarian cancer. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | The company submitted orforglipron for type 2 diabetes in the U.S., the EU, and Japan. |
| revenue | positive | probable | — | The CHMP issued a positive opinion recommending insulin efsitora alfa for the treatment of type 2 diabetes in the EU. |
| revenue | positive | probable | — | Phase 3 trials for retatrutide for obesity met their primary endpoints; a Phase 3 trial for retatrutide for type 2 diabetes met the… |
| operating_income | negative | probable | — | A Phase 3 trial was initiated for baricitinib for type 1 diabetes. |
| operating_income | negative | probable | — | Phase 3 trials were initiated for eloralintide as incretin add-on for obesity, for obstructive sleep apnea (OSA), and for osteoarthritis… |
| operating_income | negative | probable | — | A Phase 3 trial was initiated for brenipatide for major depressive disorder. |
| operating_income | negative | probable | — | A Phase 3 trial was initiated for sofetabart mipitecan for platinum-sensitive ovarian cancer, and the FDA granted Breakthrough Therapy… |
| revenue | positive | probable | — | A Phase 3 trial was initiated for sofetabart mipitecan for platinum-sensitive ovarian cancer, and the FDA granted Breakthrough Therapy… |